Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509)
Standardized SEC financial data for NAVIDEA BIOPHARMACEUTICALS, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000810509 · In Vitro & In Vivo Diagnostic Substances.
Revenue growth (YoY)
-97.2%
Return on equity
211.4%
Free cash flow
-$9.0M
Current ratio
0.32×
EPS (diluted)
$-0.09
Ratios for fiscal year 2022, standardized from SEC filings.
Income statement
USD
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
Revenue
$1.8M
$1.2M
$658K
$915K
$532K
$66K
Cost of revenue
$4K
$97K
$7K
$1K
$0
$2K
Gross profit
$1.8M
$1.1M
$651K
$914K
$532K
Standardized from NAVIDEA BIOPHARMACEUTICALS, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.